Exelixis (EXEL) Q3 2024 Earnings Call Transcript

By Yahoo! Finance | Oct 30, 2024 at 12:06 AM EST

Exelixis reported strong financial performance in Q3 2024 with significant momentum in the cabo franchise. Zanza collaboration with Merck is expected to drive revenue growth. The company is focused on expanding its pipeline with high-conviction assets for clinical differentiation and commercial success.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.